SCHEMBL9893889

SCHEMBL9893889

Fc1ccc(-c2c(-c3nn[nH]n3)nc(-c3ccsc3)n2-c2cccc(Cl)c2F)cc1Cl

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 7/20 0.64
PFKFB4 Q16877 1/20 0.38
CSNK2A1 P68400 1/20 0.36
KDM4C Q9H3R0 4/20 0.35
IDO1 P14902 1/20 0.34
KDM2B Q8NHM5 2/20 0.34
SLC22A12 Q96S37 1/20 0.33
NOTUM Q6P988 1/20 0.33
CNR1 P21554 1/20 0.33
NR1H4 Q96RI1 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
ESR2 Q92731 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9893704 0.88 MDM2 (0.69) MDM2PFKFB4KDM4CIDO1SLC22A12
SCHEMBL1436885 0.87 MDM2 (0.68) MDM2PFKFB4KDM4CIDO1SLC22A12
SCHEMBL1438114 0.85 MDM2 (0.61) MDM2PFKFB4CSNK2A1KDM4CIDO1
SCHEMBL9894070 0.84 MDM2 (0.64) MDM2PFKFB4KDM4CKDM2BSLC22A12
SCHEMBL1437412 0.83 MDM2 (0.70) MDM2PFKFB4CSNK2A1KDM4CIDO1
SCHEMBL9893758 0.82 MDM2 (0.64) MDM2PFKFB4KDM4CIDO1SLC22A12
SCHEMBL1436916 0.81 MDM2 (0.60) MDM2IDO1SLC22A12
SCHEMBL9893644 0.81 MDM2 (0.60) MDM2PFKFB4KDM4CKDM2BSLC22A12
SCHEMBL1437268 0.80 MDM2 (0.64) MDM2PFKFB4CSNK2A1KDM4CIDO1
SCHEMBL1437257 0.80 MDM2 (0.65) MDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102574785-A Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators NOVARTIS AG 2012-07-11 CN disclosed
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 MDM2 2/4885PFKFB4 3641/4885CSNK2A1 1140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.